|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PMPCA |
Gene summary for PMPCA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PMPCA | Gene ID | 23203 |
| Gene name | peptidase, mitochondrial processing subunit alpha | |
| Gene Alias | Alpha-MPP | |
| Cytomap | 9q34.3 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q10713 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23203 | PMPCA | LZE4T | Human | Esophagus | ESCC | 7.69e-09 | 2.02e-01 | 0.0811 |
| 23203 | PMPCA | LZE7T | Human | Esophagus | ESCC | 2.00e-06 | 5.93e-01 | 0.0667 |
| 23203 | PMPCA | LZE8T | Human | Esophagus | ESCC | 5.51e-07 | 2.83e-01 | 0.067 |
| 23203 | PMPCA | LZE20T | Human | Esophagus | ESCC | 1.50e-05 | 2.49e-01 | 0.0662 |
| 23203 | PMPCA | LZE22D1 | Human | Esophagus | HGIN | 9.54e-04 | 1.28e-02 | 0.0595 |
| 23203 | PMPCA | LZE24T | Human | Esophagus | ESCC | 8.24e-08 | 1.79e-01 | 0.0596 |
| 23203 | PMPCA | LZE6T | Human | Esophagus | ESCC | 4.78e-07 | 1.57e-01 | 0.0845 |
| 23203 | PMPCA | P1T-E | Human | Esophagus | ESCC | 9.20e-05 | 2.94e-01 | 0.0875 |
| 23203 | PMPCA | P2T-E | Human | Esophagus | ESCC | 3.07e-28 | 5.61e-01 | 0.1177 |
| 23203 | PMPCA | P4T-E | Human | Esophagus | ESCC | 2.58e-16 | 2.90e-01 | 0.1323 |
| 23203 | PMPCA | P5T-E | Human | Esophagus | ESCC | 7.58e-09 | 2.07e-01 | 0.1327 |
| 23203 | PMPCA | P8T-E | Human | Esophagus | ESCC | 2.11e-18 | 3.63e-01 | 0.0889 |
| 23203 | PMPCA | P9T-E | Human | Esophagus | ESCC | 3.63e-12 | 2.21e-01 | 0.1131 |
| 23203 | PMPCA | P10T-E | Human | Esophagus | ESCC | 2.56e-24 | 4.87e-01 | 0.116 |
| 23203 | PMPCA | P11T-E | Human | Esophagus | ESCC | 1.40e-11 | 5.15e-01 | 0.1426 |
| 23203 | PMPCA | P12T-E | Human | Esophagus | ESCC | 1.22e-21 | 3.46e-01 | 0.1122 |
| 23203 | PMPCA | P15T-E | Human | Esophagus | ESCC | 3.27e-21 | 3.03e-01 | 0.1149 |
| 23203 | PMPCA | P16T-E | Human | Esophagus | ESCC | 5.14e-16 | 3.14e-01 | 0.1153 |
| 23203 | PMPCA | P17T-E | Human | Esophagus | ESCC | 7.62e-08 | 4.28e-01 | 0.1278 |
| 23203 | PMPCA | P20T-E | Human | Esophagus | ESCC | 6.26e-12 | 1.83e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007259420 | Esophagus | HGIN | establishment of protein localization to organelle | 120/2587 | 422/18723 | 1.73e-15 | 4.00e-13 | 120 |
| GO:000683920 | Esophagus | HGIN | mitochondrial transport | 74/2587 | 254/18723 | 1.32e-10 | 1.32e-08 | 74 |
| GO:007058520 | Esophagus | HGIN | protein localization to mitochondrion | 43/2587 | 125/18723 | 4.43e-09 | 3.03e-07 | 43 |
| GO:007265520 | Esophagus | HGIN | establishment of protein localization to mitochondrion | 41/2587 | 120/18723 | 1.26e-08 | 7.96e-07 | 41 |
| GO:000660525 | Esophagus | HGIN | protein targeting | 78/2587 | 314/18723 | 1.08e-07 | 5.47e-06 | 78 |
| GO:000662620 | Esophagus | HGIN | protein targeting to mitochondrion | 33/2587 | 100/18723 | 7.99e-07 | 3.35e-05 | 33 |
| GO:005160417 | Esophagus | HGIN | protein maturation | 68/2587 | 294/18723 | 9.77e-06 | 2.86e-04 | 68 |
| GO:00164857 | Esophagus | HGIN | protein processing | 49/2587 | 225/18723 | 7.04e-04 | 9.52e-03 | 49 |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
| GO:0006839110 | Esophagus | ESCC | mitochondrial transport | 187/8552 | 254/18723 | 8.35e-20 | 9.81e-18 | 187 |
| GO:0072655110 | Esophagus | ESCC | establishment of protein localization to mitochondrion | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| GO:0070585110 | Esophagus | ESCC | protein localization to mitochondrion | 100/8552 | 125/18723 | 2.96e-15 | 1.77e-13 | 100 |
| GO:0006626110 | Esophagus | ESCC | protein targeting to mitochondrion | 81/8552 | 100/18723 | 3.60e-13 | 1.67e-11 | 81 |
| GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
| GO:001648514 | Esophagus | ESCC | protein processing | 134/8552 | 225/18723 | 1.81e-05 | 1.60e-04 | 134 |
| GO:007259422 | Liver | HCC | establishment of protein localization to organelle | 299/7958 | 422/18723 | 1.06e-32 | 6.10e-30 | 299 |
| GO:000660512 | Liver | HCC | protein targeting | 219/7958 | 314/18723 | 7.74e-23 | 1.49e-20 | 219 |
| GO:000683912 | Liver | HCC | mitochondrial transport | 184/7958 | 254/18723 | 2.30e-22 | 3.83e-20 | 184 |
| GO:007265512 | Liver | HCC | establishment of protein localization to mitochondrion | 98/7958 | 120/18723 | 1.18e-18 | 1.46e-16 | 98 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PMPCA | SNV | Missense_Mutation | rs543713243 | c.466N>A | p.Asp156Asn | p.D156N | Q10713 | protein_coding | tolerated(0.19) | benign(0.142) | TCGA-C8-A12Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| PMPCA | SNV | Missense_Mutation | rs143416740 | c.229N>T | p.Arg77Cys | p.R77C | Q10713 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| PMPCA | SNV | Missense_Mutation | c.998N>C | p.Asp333Ala | p.D333A | Q10713 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-D8-A27M-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | methotrexate+5 | SD | |
| PMPCA | insertion | Frame_Shift_Ins | novel | c.1342_1343insCCCGCCACCACGCCCAGCTA | p.Asp448AlafsTer32 | p.D448Afs*32 | Q10713 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PMPCA | insertion | Nonsense_Mutation | novel | c.1344_1345insTTCTTTTTGTATTTTTAGTAGAGAA | p.Val449PhefsTer6 | p.V449Ffs*6 | Q10713 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PMPCA | SNV | Missense_Mutation | rs869025293 | c.1543G>A | p.Gly515Arg | p.G515R | Q10713 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PMPCA | SNV | Missense_Mutation | c.546N>C | p.Glu182Asp | p.E182D | Q10713 | protein_coding | tolerated(0.18) | benign(0.077) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PMPCA | SNV | Missense_Mutation | novel | c.281N>C | p.Ile94Thr | p.I94T | Q10713 | protein_coding | deleterious(0) | possibly_damaging(0.864) | TCGA-MA-AA3X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| PMPCA | SNV | Missense_Mutation | c.466G>C | p.Asp156His | p.D156H | Q10713 | protein_coding | tolerated(0.31) | benign(0.082) | TCGA-MY-A5BD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| PMPCA | SNV | Missense_Mutation | c.901G>C | p.Glu301Gln | p.E301Q | Q10713 | protein_coding | tolerated(0.23) | benign(0.042) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |